SCHEMBL5032537

SCHEMBL5032537

COc1cc(N(C(=O)c2ccc(Cl)cc2Cl)c2nc(C(=O)O)c(C)s2)ccc1Cl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.38
TSHR P16473 3/20 0.36
MAPT P10636 2/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
PYGL P06737 1/20 0.35
CASP1 P29466 1/20 0.35
GAA P10253 1/20 0.35
KMT2A Q03164 3/20 0.35
TTR P02766 1/20 0.34
MRGPRX4 Q96LA9 1/20 0.34
MEN1 O00255 2/20 0.34
DCLK1 O15075 1/20 0.34
FES P07332 1/20 0.34
PIM1 P11309 1/20 0.34
CDK2 P24941 1/20 0.34
GSK3A P49840 1/20 0.34
GSK3B P49841 1/20 0.34
IRAK1 P51617 1/20 0.34
MAP4K2 Q12851 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5035259 0.94 FLT1 (0.39) CYP3A4TSHRMAPTRAB9ASMN1; SMN2
SCHEMBL5035943 0.88 CYP3A4 (0.47) CYP3A4TSHRMAPTRAB9ASMN1; SMN2
SCHEMBL5035249 0.87 LMNA (0.38) CYP3A4MAPTRAB9AKMT2AMEN1
SCHEMBL5032654 0.84 HTR2C (0.43) MAPTRAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL5032638 0.84 FLT1 (0.38) CYP3A4TSHRMAPTRAB9ASMN1; SMN2
SCHEMBL5034805 0.83 CYP3A4 (0.42) CYP3A4TSHRMAPTRAB9AGAA
SCHEMBL5035014 0.83 TRPC3 (0.41) MAPTRAB9ASMN1; SMN2ALDH1A1HPGD
SCHEMBL5032570 0.83 CNR1 (0.40) MAPTKMT2AALDH1A1KDM4ELMNA
SCHEMBL5032576 0.83 CNR1 (0.40) MAPTKMT2AALDH1A1KDM4ELMNA
SCHEMBL5035196 0.83 ALDH1A1 (0.35) CYP3A4TSHRMAPTSMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7371751-B2 Thiazole derivatives HOFFMANN-LA ROCHE INC. (US) 2008-05-13 US disclosed
EP-1694673-B1 THIAZOLE DERIVATES HOFFMANN LA ROCHE (CH) 2008-01-16 EP disclosed
EP-1694673-A1 NOVEL THIAZOLE DERIVATES F.HOFFMANN-LA ROCHE AG (CH) 2006-08-30 EP disclosed
US-20050153962-A1 Thiazole derivatives HOFFMANN-LA ROCHE INC. 2005-07-14 US disclosed
WO-2005058887-A1 NOVEL THIAZOLE DERIVATES F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050153962-A1 Thiazole derivatives CNR1, CNR2, GPR119 CYP3A4 693/4885TSHR 42/4885MAPT 3183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.